PuSH - Publikationsserver des Helmholtz Zentrums München

Magkouta, S.* ; Kollintza, A.* ; Moschos, C.* ; Spella, M.* ; Skianis, I.* ; Pappas, A.* ; Vazakidou, M.E.* ; Stathopoulos, G.T. ; Kalomenidis, I.*

Role of angiopoietins in mesothelioma progression.

Cytokine, DOI: 10.1016/j.cyto.2018.08.006 (2018)
DOI PMC
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
Background and objective: Anti-angiogenic treatment has been recently shown to be clinically beneficial for mesothelioma patients. Angiopoietins-1 and -2 are key regulators of tumor angiogenesis. Ang-1 is mainly known to promote angiogenesis and vessel stability, while Ang-2 could serve as an antagonist of Ang-1 causing vessel regression and destabilization or enhance angiogenesis in a context-dependent manner. We hypothesized that Ang-1 would promote and Ang2 would halt experimental mesothelioma by affecting tumor angiogenesis. Methods: To examine the effects of angiopoietins in mesothelioma angiogenesis and in vivo growth we constructed Ang-1 or Ang-2 overexpressing AE17 and AB1 mesothelioma cells and implanted them in the respective syngeneic animals. We also explored the clinical relevance of our observations using the human tumoral mRNAseq data available in the TCGA database. Results and conclusions: Ang-1 promotes mesothelioma angiogenesis and growth while the effect of Ang-2 is context-dependent. Low Ang-1 levels in human mesotheliomas are associated with the epitheloid subtype. Tumors of high Ang-1, or concurrent high Ang-2 and VEGF expression present high PECAM-1 and CDH5 expression, markers of vascularity and vascular stability, respectively. Our results highlight the importance of angiopoietins in mesothelioma pathophysiology and pave the way for the clinical development of novel anti-angiogenic strategies.
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Korrespondenzautor
Schlagwörter Angiopoietins ; Mesothelioma ; Tumor Angiogenesis
ISSN (print) / ISBN 1043-4666
e-ISSN 1096-0023
Zeitschrift Cytokine
Verlag Elsevier
Verlagsort Oxford [u.a.]
Nichtpatentliteratur Publikationen
Begutachtungsstatus Peer reviewed
Institut(e) Lung Health and Immunity (LHI)